4 Insights on decentralized trials for biotechs

The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs) by biopharma companies. The clinician-patient relationship will always be key to clinical trials, but decentralized aspects such as direct-to-patient shipments and telehealth are here to stay. Here are four things we have learned about DCTs that biotech companies can consider when designing a decentralized or hybrid trial.


Open PDF

Return to Insights Center

Related Insights

Related Insights

Podcast

Enabling Successful Sites, Episode 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021

Podcast

Enabling Successful Sites, Episode 3: Taking the complexity out of oncology clinical trials

Jun 28, 2024

Blog

Scientific Advances: Catalyst for Biotech Investment and Innovation in Clinical Development

Mar 12, 2024

Blog

Master Protocol Trials: What Are the Elements of Success?

Dec 1, 2021

Playbook

Insights from the 2022 R&D Innovation Survey

Feb 17, 2023

Show more